Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer.
artesunate
drug synergy
navitoclax
ovarian cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
04
03
2024
revised:
22
03
2024
accepted:
25
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
13
4
2024
Statut:
epublish
Résumé
Artesunate belongs to a class of medications derived from the sweet wormwood plant (
Identifiants
pubmed: 38610999
pii: cancers16071321
doi: 10.3390/cancers16071321
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : P30CA177558
Pays : United States